Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Combining ...

Interim data also suggested a strong trend toward improved PFS and OS when evaluating the STRIDE regimen in combination with TACE vs TACE alone.

Doctor taking notes. The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab. The following article features coverage from the International ...

Prognostic value of dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer. First-in-human phase I, ...

The phase 3 LEAP-011 study evaluated pembrolizumab plus lenvatinib vs placebo in 441 adults with histologically confirmed, locally advanced or metastatic urothelial carcinoma. The following article ...

Please provide your email address to receive an email when new articles are posted on . Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with ...

The multitargeted tyrosine kinase inhibitor (TKI) lenvatinib induced a strong tumor response in patients with previously treated advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), ...

The Food and Drug Administration (FDA) has approved the combination of pembrolizumab (Keytruda, Merck Sharp & Dohme) with lenvatinib (Lenvima, Eisai Inc) for the first-line treatment of adult patients ...

Diagnostic performance of artificial intelligence in predicting recurrence after surgical resection of hepatocellular carcinoma (HCC). Updated results of camrelizumab (Cam) plus low dose apatinib ...

The LEAP-017 trial results presented at ESMO GI 2023 are explored by Dr Marshall. John L. Marshall, MD: There is an early observation that VEGF [vascular endothelial growth factor] inhibition along ...

CHICAGO — A new first-line treatment for advanced hepatocellular carcinoma (HCC) appears to be on the horizon. The current standard is sorafenib (Nexavar, Bayer), but a new study has found that ...